WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (NURO) today announced U.S. Food and Drug Administration (FDA) De Novo authorization to market the Quell neuromodulation device as an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results